Allworth Financial LP Has $1.01 Million Stake in Danaher Corporation $DHR

Allworth Financial LP increased its stake in shares of Danaher Corporation (NYSE:DHR) by 12.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,099 shares of the conglomerate’s stock after purchasing an additional 554 shares during the quarter. Allworth Financial LP’s holdings in Danaher were worth $1,007,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Addison Advisors LLC lifted its position in Danaher by 14.1% in the 2nd quarter. Addison Advisors LLC now owns 702 shares of the conglomerate’s stock worth $139,000 after buying an additional 87 shares in the last quarter. Tillman Hartley LLC acquired a new position in shares of Danaher in the second quarter worth $212,000. Compass Capital Management Inc. raised its holdings in shares of Danaher by 6.7% during the second quarter. Compass Capital Management Inc. now owns 281,256 shares of the conglomerate’s stock worth $55,559,000 after acquiring an additional 17,641 shares in the last quarter. ProShare Advisors LLC boosted its position in Danaher by 11.2% during the second quarter. ProShare Advisors LLC now owns 116,909 shares of the conglomerate’s stock valued at $23,094,000 after purchasing an additional 11,771 shares during the last quarter. Finally, PFG Advisors boosted its position in Danaher by 19.4% during the second quarter. PFG Advisors now owns 35,488 shares of the conglomerate’s stock valued at $7,010,000 after purchasing an additional 5,774 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the transaction, the senior vice president owned 2,625 shares in the company, valued at approximately $552,352.50. The trade was a 66.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 29,728 shares of company stock worth $6,448,990 in the last ninety days. Insiders own 11.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on DHR. Guggenheim reaffirmed a “buy” rating and set a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Bank of America dropped their price objective on Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Cowen reiterated a “buy” rating on shares of Danaher in a research note on Wednesday, October 22nd. UBS Group decreased their target price on shares of Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, July 23rd. Finally, TD Cowen increased their price target on shares of Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. Eighteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $243.39.

Danaher Trading Up 0.0%

Shares of NYSE:DHR opened at $221.25 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The stock’s 50-day moving average is $205.63 and its 200-day moving average is $201.09. The company has a market cap of $156.28 billion, a P/E ratio of 45.62, a P/E/G ratio of 3.28 and a beta of 0.81. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $258.23.

Danaher (NYSE:DHR) last announced its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.17. The firm had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.71 EPS. Equities research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were issued a $0.32 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio is 26.39%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.